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Abstract
Chronic granulomatous disease (CGD) patients have impaired nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase function, resulting in poor antimicrobial activity of neutrophils, including
the inability to generate neutrophil extracellular traps (NETs). Invasive aspergillosis is the leading cause
of death in patients with CGD; it is unclear how neutrophils control Aspergillus species in healthy
persons. The aim of this study was to determine whether gene therapy restores NET formation in CGD
by complementation of NADPH oxidase function, and whether NETs have antimicrobial activity against
Aspergillus nidulans. Here we show that reconstitution of NET formation by gene therapy in a patient
with CGD restores neutrophil elimination of A nidulans conidia and hyphae and is associated with rapid
cure of preexisting therapy refractory invasive pulmonary aspergillosis, underlining the role of
functional NADPH oxidase in NET formation and antifungal activity.
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Brief report
Restoration of NET formation by gene therapy in CGD controls aspergillosis
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Chronic granulomatous disease (CGD)
patients have impaired nicotinamide ad-
enine dinucleotide phosphate (NADPH)
oxidase function, resulting in poor antimi-
crobial activity of neutrophils, including
the inability to generate neutrophil extra-
cellular traps (NETs). Invasive aspergillo-
sis is the leading cause of death in pa-
tients with CGD; it is unclear how
neutrophils control Aspergillus species
in healthy persons. The aim of this study
was to determine whether gene therapy
restores NET formation in CGD by comple-
mentation of NADPH oxidase function,
and whether NETs have antimicrobial ac-
tivity against Aspergillus nidulans. Here
we show that reconstitution of NET forma-
tion by gene therapy in a patient with CGD
restores neutrophil elimination of A nidu-
lans conidia and hyphae and is associ-
ated with rapid cure of preexisting therapy
refractory invasive pulmonary aspergillo-
sis, underlining the role of functional
NADPH oxidase in NET formation and
antifungal activity. (Blood. 2009;114:
2619-2622)
Introduction
Activated neutrophils kill microbes intracellularly after phagocyto-
sis and by extracellular mechanisms, including neutrophil extracel-
lular traps (NETs), which are composed of chromatin decorated
with granular proteins.1 NETs bind bacteria1 and fungi2 and expose
antimicrobial molecules. Generation of NETs requires reactive
oxygen species produced by the nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase.3
Chronic granulomatous disease (CGD) is caused by mutations
in genes encoding NADPH oxidase subunits. CGD patients do not
produce reactive oxygen species, kill microbes poorly, and are
susceptible to recurrent life-threatening infections.4 Aspergillus spp
infections cause pneumonia and disseminated disease and are the
leading cause of death in these patients.4-6
It is unclear how Aspergillus infections are controlled in healthy
persons.7-13 In CGD patients, these infections are frequently
refractory to antifungal therapy, treatment with interferon-, or
granulocyte transfusions.5 Here we show that the recently discov-
ered NADPH oxidase-dependent microbicidal pathway through
NETs1-3 is efficient against Aspergillus nidulans conidia and
hyphae in vitro and that restoration of NET formation by GT of
X-CGD aided clearing severe invasive A nidulans infection in vivo.
Methods
Gene therapy
We treated an 8.5-year-old boy with X-linked gp91phox-deficient CGD and
therapy refractory A nidulans lung infection with a monocistronic long
terminal repeat-driven gamma-retroviral SF71gp91phox vector (see supple-
mental data, available on the Blood website; see the Supplemental Materials
link at the top of the online article). The protocol for the patient’s treatment
was approved by the ethics review board of the University Children’s
Hospital Zurich and the Swiss Expert Committee for Bio-Safety, after
written informed consent from his parents in accordance with the Declara-
tion of Helsinki. For follow-up monitoring, gp91phox expression was
measured by fluorescence-activated cell sorter (FACS) on peripheral
neutrophils after 30 minutes of staining at room temperature with 10 g/mL
gp91phox-fluorescein isothiocyanate (FITC) antibody (Anti-Flavocyto-
chrome b558, clone 7D5, MBL). NADPH oxidase activity was measured
by standard dihydrorhodamine and nitroblue tetrazolium tests (supplemen-
tal materials). Bone marrow colony assays and determination of proviral
gp91phox sequences in genomic DNA were performed as described.14
NET induction
NET formation was visualized as described (supplemental materials) and
quantified after stimulation of 5 104 neutrophils for 3 hours with 40 nM
phorbol 12-myristate 13-acetate (PMA) and staining the NET-DNA with 1 M
Sytox green (Invitrogen) in a black 96-well plate (BD Biosciences). The plates
were read in a fluorescence microplate reader (Victor,3 PerkinElmer Life and
Analytical Sciences) with a filter setting of 485 nm/535 nm (excitation/emission).
NET antifungal activity
The A nidulans strain used was isolated from bronchoalveolar lavage fluid
of the patient; conidia were grown and collected as described.7 Neutrophils
after GT were stained with gp91phox-FITC antibody and sorted by FACS
(FACSAria, BD Biosciences) into gp91phox-negative (gp91phox) and -posi-
tive (gp91phox) populations. A total of 105 neutrophils were activated with
PMA (40 nM) at 37°C for 4 hours in a 96-well plate, and then infected with
conidia (multiplicity of infection A nidulans/neutrophils  0.5) plus or
minus prior digestion of NETs with 10 U/mL of Micrococcal Nuclease
(MNase, Worthington Biochemical) for 30 minutes. Afterward the plates
were centrifuged for 5 minutes at 400g and incubated for 16 hours at 37°C,
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allowing germination and hyphal outgrowth. Alternatively, 5  104 conidia
were incubated for 12 hours at 37°C to allow hyphal outgrowth; then
105 neutrophils were added, centrifuged for 5 minutes at 400g, and
incubated for 2 and 5 hours with PMA (40 nM) to induce NET formation,
plus or minus 10 U/mL MNase. Fungal growth was quantified with XTT
(Invitrogen) as described.15
Results and discussion
In healthy subjects, NETs might be essential to eliminate fungi
because hyphae are too large to be phagocytosed.7,9,12,13,16-21 CGD
patients are unable to make NETs.3 Indeed, neutrophils of our
X-CGD patient could only make NETs and inhibit growth of
A nidulans after genetic complementation by GT. Neutrophils
expressing functional gp91phox increased from 0% to 26% to 29% 6
weeks after GT (Figure 1A-B), then decreased and leveled at
approximately 16% for up to 3 months. The A nidulans infection
completely cleared 6 weeks after GT (Figure 1C), correlating with
the rise in neutrophils with NADPH oxidase activity.
The patient’s neutrophils did not make NETs before GT as
analyzed by fluorescence (not shown), immunofluorescence, and
scanning electron microscopy (Figure 2A-B, D-E).3 After GT, the
patient’s neutrophils made NETs (Figure 2C,F), the percentage of
cells releasing NET-DNA (28%; Figure 2G) correlating with the
level of oxidase chimerism (Figure 1B). Activation of sorted
neutrophils showed that reconstitution with functional NADPH
oxidase allowed corrected CGD neutrophils to make NETs
(Figure 2H).
To test whether efficient eradication of the patient’s infection
was the result of the recovered ability to make NETs, neutro-
phils were infected with the A nidulans strain isolated from the
patient. Approximately 80% of conidia germination (Figure 2I)
and 45% of hyphal growth (Figure 2J) were inhibited by CGD
gp91phox neutrophils, comparable with the antimicrobial activ-
ity of control neutrophils. CGD gp91phox neutrophils were
inefficient in controlling fungal growth (Figure 2I-J, supplemen-
tal Figure 1). When NETs were dismantled with MNase before
infection, fungicidal activity was abrogated to that of CGD
gp91phox neutrophils.
In the absence of NETs, control of hyphal growth was indepen-
dent of NADPH oxidase activity: when neutrophils were infected
after 2-hour PMA stimulation, before NETs had been made, CGD
gp91phox, CGD gp91phox, and neutrophils from healthy donor
controlled growth of A nidulans with similar modest efficiency
(Figure S2) in a NET-independent fashion because antimicrobial
activity was not affected by MNase. This limited NET-independent
antimicrobial activity, presumably by conidia phagocytosis, degranu-
lation, or unknown mechanisms, suggests an NADPH oxidase-
independent antifungal mechanism, clinically ineffective before
GT. These data propose that the patient’s clearance of fungal
infection after GT was controlled by NETs. Definitive in vivo proof
is obviously technically impossible.
Figure 1. Restoration of NADPH oxidase function. (A) Hematopoietic reconstitution and gene marking after GT. Absolute neutrophil counts (left y-axis), quantification of
gene-modified cells in peripheral neutrophils by quantitative polymerase chain reaction and quantification of neutrophils with NADPH oxidase activity by DHR test (right y-axis)
are shown. When the percentage of transduced neutrophils decreased, granulocyte colony-stimulating factor (5 g/kg per day subcutaneously) was administered on days 49
to 57 and on day 64. (B) Reconstitution of NADPH oxidase activity. Before and 6 weeks after GT, gp91phox protein expression was measured by FACS analysis after 30 minutes
of staining with 10 g/mL gp91phox-FITC antibody. Superoxide production was assessed by oxidation of DHR on stimulation with PMA and by reduction of nitroblue tetrazolium
to formazan (dark precipitate) after stimulation with opsonized zymosan. The thresholds were determined using unstained (FACS) or unstimulated (DHR) cells for each
experiment. (C) PET-CT scan. Before GT, PET-CT scan showed several active infectious foci with fluorine-18-fluoro-2-deoxy-D-glucose uptake in both lungs of the patient (red
arrows); the infection cleared 6 weeks after administration of gene-corrected cells. In green, physiologic FDG uptake in heart (arrow), kidneys (arrowheads), bladder (*), and
brain (diamond) are indicated for reference.
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Alveolar macrophages probably constitute the first line of
defense to conidia that escape mucociliary clearance in healthy
persons.13,16 Whether reconstituted NADPH oxidase function in
alveolar macrophages also contributed to microbial killing in the
patient presented is difficult to assess. In neutrophils, however,
conidia resist intracellular killing because of their relative tolerance
to reactive oxygen species.7,9,12,19-22 Our results suggest that conidia
are killed mainly extracellularly rather than after phagocytosis.
Both conidia and hyphae get ensnared by neutrophils and probably
killed within NETs by concentrated antimicrobials. Cooperation of
gp91phox and gp91phox neutrophils in NET antifungal activity is
doubtful because we showed that gp91phox neutrophils do not
make NETs when coincubated with gp91phox neutrophils (un-
sorted cells in Figure 2F-G),10 suggesting that the amount of H2O2
released by gp91phox neutrophils is insufficient to induce NETs in
gp91phox cells.3
A GT approach to treat CGD may be used to overcome recalcitrant,
life-threatening infections but is currently limited as salvage therapy to
experimental studies in selected patients with very poor performance
status and lacking an human leukocyte antigen-identical hematopoietic
stem cell donor.4 GT was rapidly beneficial to our CGD patient who had
suffered from an otherwise incurable fungal infection. Until day 86 after
GT, there was no clonal dominance in bone marrow culture-derived
CD34 cells (not shown) or expansion of gene-corrected cells in blood
(Figure 1A). There is a risk, however, of insertional mutagenesis by
transactivating retroviral vector insertions into proto-oncogenes, as
shown in a recent GT trial with 2 adult CGD patients who developed
monosomy 7 and myelodysplastic syndrome (M. Grez, Institute of
Biomedical Research, Georg-Speyer-Haus, Frankfurt, Germany, oral
communication, April 2009) using the same gamma-retroviral
SF71gp91phox vector.14 In addition, 5 patients developed leukemia in
2 GT trials in children with severe combined immunodeficiency.23,24
These experiences mandate the careful follow-up of patients.
In conclusion, we show that the severe immunodeficient
phenotype and the high susceptibility to Aspergillus infection of
CGD patients might be linked to the absence of NETs, and that
restoration of NADPH oxidase function and NET formation by
GT leads to rapid cure of refractory invasive aspergillosis in
X-linked CGD.
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